EUCTR2022-000073-12-ES进行中（未招募）1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 345
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1. Subject is willing and able to provide informed consent
- •2. Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions
- •3. Disease status including:
- •a. Histological or cytological confirmation of LMS arising at any anatomic site except bone sarcoma
- •b. Unresectable or metastatic, relapsed or refractory disease
- •c. Measurable disease per RECIST 1.1 criteria
- •d. Disease progression on previous treatment before screening or intolerability to other oncology treatments
- •Demographics:
- •4. Age =18 years
- •5. Male or female
- •Performance status:
- •6. ECOG PS score of 0 or 1
- •Hematopoietic:
- •7. Absolute neutrophil count =1500/mm3 without the use of growth factors in the past 7 days
- •8. Platelet count =100000/mm3 without platelet transfusion in the past 14 days
- •9. Hemoglobin =9 g/dL (packed red blood cell transfusion is not allowed within 7 days)
- •10. Bilirubin = upper limit of normal (ULN)
- •11. Aspartate aminotransferase or alanine aminotransferase <1.5 times the ULN
- •12. Subjects with liver metastases may be enrolled
- •13. Subjects with well-controlled asthma (eg, use of rescue medications <2 times per week over the last 12 months) or chronic obstructive pulmonary disease (eg, no exacerbations over the prior 3 months) may be enrolled.
- •14. Creatinine <1.5 times normal OR creatinine clearance = 60 mL/min
- •Prior therapeutics:
- •15. Toxicity from prior therapies recovered to Grade =1 or subject’s baseline, except for alopecia. In addition, endocrinopathies associated with prior immunotherapy-based treatments that are well controlled on replacement medication are not exclusionary.
- •Chemotherapy and targeted therapy:
- •16. At least 1 prior systemic cytotoxic or targeted therapy regimen for LMS
- •17. At least 4 weeks since prior surgery and recovered in the opinion of investigator
- •18. Capable of swallowing oral medication
- •19. Women of childbearing potential (WOCBP; as defined by the Clinical Trials Facilitation and Coordination Group [CTFG]) must have a negative serum pregnancy test at screening and agree to abstinence or the use at least one of the following highly effective forms of contraception (with a failure rate of <1% per year when used consistently and correctly) (Clinical Trials Facilitation and Coordination Group 2020). Contraception or abstinence must be continued for the duration of the study and for up to 90 days after the last dose of study drug:
- •Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- •-Intravaginal
- •-Transdermal
- •Progestogen-only hormonal contraception associated with inhibition of ovulation:
- •-Injectable
- •-Implantable
- •Intrauterine device
- •Intrauterine hormone-releasing system
- •Bilateral tubal occlusion
- •Vasectomized partner with confirmed azoospermia
- •All females will be considered of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea in the appropriate age group without other known or suspected cause) or have been sterilized surgically (eg, bilateral salpingectomy, hysterectomy, bilateral oophorectomy).
- •20. Lactating females are not eligible unless they have agreed not to breastfeed their infants during treatment and for a period of 1 month following completion of treatment.
- •21. Males who are sexually active with WOCBP who have not had a vasectomy must agree to use a barrier m
排除标准
- •1. Received temozolomide or DTIC at any time
- •2. Any other systemic anticancer therapy including investigational agents =3 weeks before initiation of study treatment. Additionally, subjects may not have received radiation =3 weeks before initiation of study treatment.
- •3. Known intolerance to DTIC or one or more of the excipients in unesbulin.
- •4. Co-existing active infection or any co-existing medical condition likely to interfere with study procedures, including:
- •a. Significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease), myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring therapy, unstable arrhythmia or a need for anti-arrhythmic therapy, or evidence of ischemia on ECG, marked baseline prolongation of QT/QTc (corrected QT) interval, eg, repeated demonstration of a QTc interval >500 msec (Long QT Syndrome [congenital])
- •5. Known human immunodeficiency virus, hepatitis B virus, or hepatitis C virus positivity
- •6. History of solid organ transplantation
- •Therapeutics:
- •7. Known or suspected allergy or immediate or delayed hypersensitivity to unesbulin or dacarbazine, their excipients, or any agent given in this study
- •Gastrointestinal:
- •8. Bowel obstruction, malabsorption, or other contraindication to oral medication
- •9. Gastrointestinal disease or other conditions that could affect absorption. Active peptic ulcer disease or previous history of gastric perforation within the last 2 years
- •10. Inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), diverticulitis, cholecystitis, symptomatic cholangitis, or appendicitis
- •Wounds/surgery:
- •11. Serious non-healing wound, ulcer, or bone fractures
- •12. Major surgery, open biopsy, or significant traumatic injury that has not recovered, in the opinion of the investigator, within 28 days of baseline
- •13. Mucosal or internal bleeding
- •Concomitant medications:
- •14. Concomitant strong CYP1A2 inhibitors (such as fluoroquinolones [broad spectrum quinolone antibiotics, including enoxacin and ciprofloxacin] and selective serotonin reuptake inhibitor [SSRI] agents fluvoxamine and fluoxetine) should be avoided on the same day that DTIC or unesbulin is administered. CYP1A2 inhibitors may inhibit the conversion of DTIC to its active metabolite and may increase the exposure of unesbulin.
- •15. Concomitant use of moderate CYP1A2 inducers (such as phenytoin, rifampin, ritonavir, teriflunomide, and barbiturates) and chronic use of marijuana. CYP1A2 inducers may increase the conversion of DTIC to its active metabolites.
- •16. Coadministration of acid-reducing agents should be avoided approximately 4 hours before and after unesbulin administration.
- •17. Ongoing, concomitant use of oral non-steroidal anti-inflammatory medications for more than 2 years for chronic conditions.
- •18. Prior malignancies, other than LMS, that required treatment or have shown evidence of recurrence (except for non-melanoma skin cancer, adequately treated cervical carcinoma in situ, prostate cancer in situ or any other low risk malignancy that is approved by the medical monitor) during the 5 years before initiation. Cancer treated with curative intent more than 5 years previously and without evidence of recurrence is not an exclusion.
- •19. Known coagulopathy or bleeding diathesis. Subjects on anti-coagulation should be monitored closely and International Normalized Ratio within normal range.
- •20. Prior or ongoing clinically significant illness, m
研究者
相似试验
进行中（未招募）
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-HUPTC Therapeutics, Inc.345
招募中
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-PLPTC Therapeutics, Inc.345
进行中（未招募）
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-FRPTC Therapeutics, Inc.345
招募中
1 期
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSISTreatment naïve patients with MFMedDRA version: 20.0Level: PTClassification code: 10028537Term: Myelofibrosis Class: 100000004864CTIS2023-506139-13-00Karyopharm Therapeutics Inc.304
进行中（未招募）
1 期
A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMAEUCTR2005-004710-33-GBCambridge University Hospitals NHS Foundation Trust34